StockData
Telomir Pharmaceuticals, Inc. logo

Telomir Pharmaceuticals, Inc. (TELO) stock

TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.49−0.01 (-1.96%)

Close on Nov 13, 2026Market cap $33.74MP/E –Yield –

Earnings

Telomir Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Telomir Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Telomir Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Telomir Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Telomir Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
    Update
  2. Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular
    Update
  3. Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma
    Update
  4. Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
    Update
  5. Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity
    Update
  6. Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in
    Update
  7. 8-K exhibit EX-99.1
    Update
  8. Pharmaceuticals Announces Pricing of Initial Public Offering
    Update
  9. Pharmaceuticals Announces Closing of Initial Public Offering
    Update

See a number that looks wrong?